Source comparison
CJC-1295 Dosing: Protocol Comparison
2× weekly 150–200mcg 300–400mcg 30–60 min before sleep Standard muscle growth protocol. Aligns with extended half-life, minimises injection frequency Optimal for most research applications. Balances convenience with sustained GH elevation 3× weekly 100–150mcg
This comparison does not assign a generated winner or score.
- 2× weekly
- 150–200mcg
- 300–400mcg
- 30–60 min before sleep
- Standard muscle growth protocol. Aligns with extended half-life, minimises injection frequency
- Optimal for most research applications. Balances convenience with sustained GH elevation
- 3× weekly
- 100–150mcg
- 300–450mcg
- Higher-frequency protocol for users prioritising more stable plasma levels
- Marginal benefit over 2× weekly. Additional injection offers minimal pharmacokinetic advantage given 6–8 day half-life
- Daily
- 50–100mcg
- 350–700mcg
- Mimics older protocols designed for shorter-acting peptides
- Not recommended. Daily dosing designed for GHRP-2/GHRP-6, not extended-release CJC-1295; increases cost and injection burden without proportional efficacy gain
- Single weekly
- 200–300mcg
- Ultra-low-frequency protocol for minimal intervention
- Suboptimal. Single large bolus creates uneven plasma concentration curve; trough levels drop below therapeutic threshold by day 6–7